Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based <i>MET</i> Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung Cancer.

Lung Cancer (Auckland, N.Z.)·2026

Same author

LAMPAD: An Integrated Circulating Tumor DNA-Based Model for Predicting Potential Cure in Patients With Resected NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Same author

Co-expression pattern of CD8, CXCR5 and CXCL13 in tumor microenvironment predicts favorable efficacy of immunotherapy in lung adenocarcinoma.

European journal of pharmacology·2026

Same author

The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors.

Journal of controlled release : official journal of the Controlled Release Society·2026

Same author

Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study.

The Lancet. Oncology·2025

Same author

Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastases.

Journal for immunotherapy of cancer·2025

Search research articles

Related Experiment Video

Updated: May 11, 2026

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

NSCLC: Five trials to watch.

Wei-Chi Luo¹, Shu-Xin Zhong¹, Si-Yang Maggie Liu¹

¹Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.

Med (New York, N.Y.)

|May 9, 2026

Summary

This summary is machine-generated.

Advances in circulating tumor DNA (ctDNA) and novel therapies like KRAS G12D inhibitors offer new hope for managing non-small cell lung cancer (NSCLC) as a chronic condition. Clinical trials are exploring these innovations to improve patient outcomes.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Related Experiment Videos

Last Updated: May 11, 2026

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Area of Science:

Oncology
Molecular Biology
Clinical Trials

Background:

Non-small cell lung cancer (NSCLC) remains a significant challenge, despite progress in targeted therapy and immunotherapy.
Current treatment paradigms do not consistently manage NSCLC as a chronic disease.

Purpose of the Study:

To review emerging strategies and clinical trials aimed at transforming NSCLC management.
To highlight the potential of ctDNA/MRD-guided adaptive treatment and novel therapeutic agents.

Main Methods:

Review of recent advancements in NSCLC treatment.
Identification of key emerging therapeutic classes: KRAS G12D inhibitors, TROP2-ADCs, and PD-1/VEGF bispecific antibodies.
Analysis of five pivotal clinical trials influencing NSCLC care.

Main Results:

Circulating tumor DNA (ctDNA) and molecular residual disease (MRD) monitoring enable adaptive treatment strategies.
Novel agents show promise in overcoming treatment resistance and improving efficacy.
Emerging clinical trials are poised to significantly impact precision treatment for NSCLC.

Conclusions:

The integration of ctDNA/MRD-guided therapy and novel agents represents a paradigm shift towards chronic NSCLC management.
Ongoing clinical trials are critical for validating these advancements and realizing the vision of long-term disease control.